HEY2 and prostate carcinoma: Similarly, growing evidence indicates that HEY2 is overexpressed and significantly contributes to the development of various human cancers, including osteosarcoma [84], prostate cancer [85], pancreatic ductal adenocarcinomas, and hemangiomas [86], which highlights HEY2’s potential as a predictive biomarker in oncology.